All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Dynamic contrast-enhanced (DCE) magnetic resonance (MR) imaging is the most sensitive modality for breast cancer detection, and is commonly used for the preoperative evaluation of newly diagnosed breast cancer cases \[[@pone.0195756.ref001]--[@pone.0195756.ref003]\]. Morphological features and patterns of contrast enhancement on MR imaging provide important information, not only of tumor histological features, such as vascularization, but also survival outcome prediction \[[@pone.0195756.ref004]--[@pone.0195756.ref006]\].

Regarding evaluating kinetic features, there are several methods to assess the kinetic enhancement patterns of breast tumor obtained from DCE MR imaging \[[@pone.0195756.ref007]\]. For quantitative analysis, pharmacokinetic models, such as Tofts and extended Tofts models, are standard for analyzing DCE MRI data. These models are suitable when the tissue under investigation is weakly vascularized or in the presence of a negligible intravascular concentration of contrast agent \[[@pone.0195756.ref008], [@pone.0195756.ref009]\]. The Tofts model considers intravascular space as one compartment and extracellular extravascular space as the other compartment, excluding the functionality of intravascular space. Computation of pharmacokinetic parameters requires curve fitting to concentration--time curves for multiple voxels. This is typically time-consuming and hinders online access of pharmacokinetic maps by radiologists \[[@pone.0195756.ref010]\]. Most commonly, breast kinetic enhancement patterns are measured semi-quantitatively using modest temporal resolution with at least two to three post-contrast T1-weighted acquisitions, with k-space centered at approximately 90--120 seconds after contrast injection for the first post-contrast images \[[@pone.0195756.ref007]\]. Using the data obtained at each of these time points, a time-signal intensity curve can be determined for a given lesion or region of interest. Despite its high utility in functional analysis, kinetic assessment using a manually drawn region of interest (ROI) is limited because it only reflects partial pixel information of the lesion. Moreover, ROI placement and interpretation are operator-dependent and time-consuming.

Despite the controversy of whether it improves the diagnostic performance of MR imaging, computer-aided diagnosis (CAD) systems have the advantage of being easy to use, and are widely clinically available to automatically assess kinetic information and perform volumetric analysis for breast lesions \[[@pone.0195756.ref011]--[@pone.0195756.ref014]\]. CAD systems eliminate the need for labor-intensive tasks, such as manual drawing of ROI by a technician or radiologist. In addition, CAD has the potential to increase observer reproducibility in DCE MR imaging by performing automatic and quantitative analysis of the contrast material uptake \[[@pone.0195756.ref015]--[@pone.0195756.ref017]\].

The correlation between kinetic parameters on CAD and the histological characteristics of breast cancer have been evaluated \[[@pone.0195756.ref018]\]. CAD-derived kinetic information may be used to assess tumor aggressiveness, including hormone receptor status and histologic grade. In terms of survival outcomes, Yi et al. \[[@pone.0195756.ref019]\] reported that a smaller reduction in the washout component on DCE MR imaging assessed using CAD after neoadjuvant chemotherapy (NAC) in breast cancer patients was independently associated with a worse recurrence-free survival (RFS) and overall survival \[[@pone.0195756.ref019]\]. In a preoperative setting, Dietzel et al. \[[@pone.0195756.ref020]\] evaluated the potential of DCE MR imaging to predict disease-related death using CAD on 115 patients, finding that total tumor volume, initial peak enhancement, and time to peak enhancement showed a negative correlation with survival. The persistent curve type, however, showed a positive correlation with survival. Baltzer et al. \[[@pone.0195756.ref021]\] analyzed the enhancement kinetics of 59 patients using CAD and found that a washout component could be identified as a significant and independent predictor of distant metastasis occurrence. However, because their studies only included a small sample size, patients in NAC setting, or a qualitative assessment using in-house software, there is currently a lack of reports evaluating the correlation between preoperative MR imaging kinetic parameters assessed using a commercially available CAD with recurrence outcomes in patients with breast cancer.

Therefore, the purpose of our study was to evaluate whether the kinetic features of preoperative MRI, assessed using CAD, can predict survival outcomes in patients with newly diagnosed invasive breast cancer.

Materials and methods {#sec006}
=====================

Patients {#sec007}
--------

This retrospective study was approved by the Institutional Review Board of the Samsung Medical Center (SMC IRB 2017-03-057) and waived the need for informed patient consent.

Between March and December 2011, 823 consecutive women (mean age of 50 years, range 24--85 years) who had undergone surgery for invasive breast cancer were identified. The inclusion criteria for our study were as follows: (a) completion of preoperative DCE MR imaging with CAD at our institution, (b) initial unilateral breast biopsy-proven malignancy with a final pathologic diagnosis of invasive breast carcinoma, (c) a lesion manifesting as a mass on MR imaging. We identified 753 invasive breast carcinomas that met these criteria. We excluded cases where MR imaging was performed after diagnosis by vacuum-assisted or excisional biopsy (n = 97). Patients treated with NAC (n = 81), those who underwent breast MR imaging with a 3-T scanner (n = 264), and those who had a follow-up period of less than 3 months (n = 10) were also excluded. To exclude any magnetic strength effects during the MR examination, we only included patients who underwent 1.5-T MRI, ensuring that the MR images were obtained under homogeneous conditions. Finally, 301 women, aged 26--80 years (mean age 51 years) were included in our study. [S1 Dataset](#pone.0195756.s001){ref-type="supplementary-material"} provides detailed characteristics of patients (online). The mean interval between preoperative MR examination and surgery was 13 days (range 1--37 days).

MR imaging protocol {#sec008}
-------------------

MR imaging was performed using a 1.5-T system (Achieva; Philips Medical Systems, Best, The Netherlands) with a dedicated bilateral phased-array breast coil, with the patient in a prone position. The MR imaging examination consisted of turbo spin-echo T1- and T2-weighted sequences, and a three-dimensional DCE sequence. The DCE MR imaging sequences were performed using the following parameters: repetition time (TR) = 6.5 ms, echo time (TE) = 2.5 ms, slice thickness = 1.5 mm, flip angle = 10°, matrix size = 376 × 374 mm, field of view (FOV) = 32 × 32 cm. Axial DCE MR imaging was performed using 1 precontrast and 6 postcontrast dynamic series. Contrast-enhanced images were acquired 30, 90, 150, 210, 270, and 330 seconds after the contrast material injection. The length of each dynamic series was 60.05 seconds. A 0.1 mmol/kg bolus of gadobutrol (Gadovist; Bayer Healthcare Pharmaceutical, Berlin, Germany) was injected for dynamic contrast imaging, before a 20-mL saline flush.

Assessment of MR imaging and computer-aided diagnosis {#sec009}
-----------------------------------------------------

The DCE MR images were transferred to a CAD system (CADstream, version 4.1.3, Merge Healthcare, Chicago, IL, USA) that analyzed the signal intensities within each voxel of the FOV obtained during the dynamic sequences. The American College of Radiology Breast Imaging Reporting and Data System (ACR BI-RADS) MR lexicon \[[@pone.0195756.ref022]\] defined a persistent kinetic pattern as a continuous increase in signal over time. A plateau is defined as a signal intensity that does not change over time, after an initial rise. When the signal intensity decreases by more than 10%, after its highest point following its initial rise, it is defined as a washout. Using CAD stream, a color overlay showing the changes in signal intensity over time was automatically generated in all slices using a predefined minimum threshold. We defined the minimum threshold as 50%, or a greater increase in pixel-by-pixel comparison between the precontrast and second post-contrast images. When the relative enhancement increase was more than 100% of the precontrast image, it was classified as "rapid uptake," and when it was 50--100% it was classified as "medium uptake." When the signal intensity continued to show an increase of more than 10% in the sixth postcontrast-enhanced images, compared to the second postcontrast-enhanced images, it was classified as "persistent." When the signal intensity showed a decrease of more than 10%, it was classified as a "washout," and when the signal intensity continued to show within a 10% range, it was classified as a "plateau." We maintained a single threshold value for early and delayed phase enhancements across all patients. Volumetric assessment of the kinetic components refers to the assessment of the percentage volume of each kinetic component found within the tumors at both early and delayed phases of enhancement. The CAD reports included the following kinetic features: the initial peak enhancement values, proportions of early phase medium and rapid enhancements, and the proportion of delayed phase persistent, plateau, and washout enhancements. The following three kinetic curve patterns presented by CAD were also included in the CAD reports: type 1, delayed persistent enhancement pattern; type 2, delayed plateau enhancement pattern; and type 3, delayed washout enhancement pattern. The CAD reports were stored prospectively by interpreting radiologists, and square ROI of the entire tumor was automatically segmented when an operator chose the image slice showing the largest diameter. For cases that had multiple cancers on the MRI, we used the values of the index cancer.

The MR imaging findings were retrospectively evaluated according to BI-RADS MR lexicon \[[@pone.0195756.ref022]\] by two board-certified radiologists (S.Y.N., E.S.K., with 6 and 10 years of experience in breast MR imaging, respectively, in consensus. In cases with discrepancy in interpretation between the two readers, a third radiologist (J.S.C. with 7 years of experience in breast MR imaging) reviewed the images to reach a consensus. The radiologists assessed the shape (oval, round, or irregular), margin (circumscribed, irregular, or spiculated), and internal enhancement characteristics (homogeneous, heterogeneous, rim, or dark internal septation) of each mass.

Histopathological features {#sec010}
--------------------------

The following parameters of the pathological reports of either breast-conserving surgery or mastectomy specimens were reviewed: pathologic diagnosis, histologic grade, surgical margin status, presence of an extensive intraductal component (EIC), lymphovascular invasion (LVI), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 expression status. Positivity for ER and PR was defined using a cut-off value of greater than 1% positively stained nuclei. Immunohistochemical HER2 scores of 3+ (strong homogeneous staining) were considered positive. In cases of HER2 scores of 2+, HER2 gene amplification was confirmed using silver in situ hybridization (SISH). For Ki-67 expression status, nuclear staining of at least 14% was considered to indicate a high level of expression. Breast cancers were divided into three molecular subtypes based on the immunohistochemical or SISH findings for ER, PR, HER2 as follows: luminal (hormone receptor positive and any of HER2 status), HER2-enriched (hormone receptor negative and HER2 positive), and triple-negative (hormonal receptor negative and HER2 negative) \[[@pone.0195756.ref023]\]. Tumors were divided into three histological groups: invasive ductal carcinoma, invasive lobular carcinoma, and others. The surgical margin status was classified as positive or close (\<2 mm), or negative. Because frozen biopsy was routinely performed during surgery at our institution, immediate repeat excision was performed on the same day for patients showing a positive margin in the frozen biopsy. Only the final results of the surgical margin were analyzed. We reviewed the patients' medical records to identify whether they received adjuvant chemotherapy, adjuvant radiation therapy, or adjuvant endocrine therapy. We also reviewed the TNM stage after surgery and the follow-up information from the medical records including imaging studies for each patient.

Statistical analyses {#sec011}
--------------------

Breast cancer recurrence was defined as local recurrence (limited to the ipsilateral breast or chest wall), regional recurrence (ipsilateral axillary, infraclavicular, or supraclavicular lymph nodes), contralateral breast, or distant metastasis to other parts of the body. DFS and disease-specific survival (DSS) were calculated from the date of surgery to that of breast cancer recurrence, the date of death, the date last known to have no evidence of disease, or the date of the most recent follow-up. Patients without an event were censored at the date of the most recent follow-up, regardless of whether they were scheduled for future follow-up or they had been lost to follow-up.

The Cox proportional hazards model was used to determine the association between MR imaging kinetic features derived from CAD and DFS or DSS. The peak signal intensity and volumetric assessment of different kinetic components were compared to the clinical-pathological variables using a Student's *t-*test and analysis of variance (ANOVA).

Statistical significance was set at *P* \< .05. Variables with *P* \< .05 on the univariate analysis were entered as the input variables for a multivariate model. All statistical analyses were performed by a dedicated statistician using R statistical software (version 3.2.4; R Foundation for Statistical Computing, Vienna, Austria).

Results {#sec012}
=======

Patients characteristics and survival outcome {#sec013}
---------------------------------------------

The mean follow-up time was 55.2 months (range, 5--72 months). There were 32 recurrences in 32 patients (7 local, 6 regional, 5 contralateral breasts, 14 distant) at a mean of 33.3 months (range, 5--72 months).

Of the 301 study lesions, 272 (90.4%) were invasive ductal carcinomas, 11 (3.7%) were invasive lobular carcinomas, and 18 (5.9%) were other types of carcinoma. Of the 18 other carcinomas, 5 were mucinous, 3 were mixed invasive ductal and mucinous, 3 were invasive apocrine, 3 were invasive micropapillary, 2 were medullary, 1 was adenoid cystic, and 1 was tubular. Among 301 patients, 59 (19.6%) patients underwent mastectomy and 242 (80.4%) patients received breast-conserving surgery. For resection margin, most were negative (80.1%) while 19.9% were close (\<2mm) or positive.

Survival analysis: Univariate and multivariate {#sec014}
----------------------------------------------

Univariate analysis of clinicopathological variables associated with DFS is presented in [Table 1](#pone.0195756.t001){ref-type="table"}. Among the clinical-pathological variables, T2 stage (DFS hazard ratio, 2.053; *P* = .049), N3 stage (DFS hazard ratio, 4.836; *P* = .005), histologic grade 2 (DFS hazard ratio, 4.490; *P* = .048), histologic grade 3 (DFS hazard ratio, 9.782; *P* = .002), ER negativity (DFS hazard ratio, 5.243; *P* \< .0001), PR negativity (DFS hazard ratio, 4.402; *P* = .0001), triple-negative subtype (DFS hazard ratio, 7.093; *P* \< .0001), and not receiving adjuvant endocrine therapy (DFS hazard ratio, 3.968; *P* = .0001) were associated with worse DFS outcomes. With regard to the CAD-derived kinetic features, the mean peak enhancement value of the recurrence group was higher than that of the non-recurrence group (310.19% \[median, 305%; interquartile range, 236--384.8%\] vs 252.13% \[median, 235%; interquartile range, 191--297%\], respectively) and the higher peak signal enhancement (DFS hazard ratio, 1.004; *P* = .001) was significantly associated with a worse DFS on univariate analysis (Figs [1](#pone.0195756.g001){ref-type="fig"} and [2](#pone.0195756.g002){ref-type="fig"}; [Table 2](#pone.0195756.t002){ref-type="table"}). Although the mean value of the washout component was higher in the recurrence group than non-recurrence group (39.19% \[median, 40.5%; interquartile range, 24.50--54.25%\] vs 38.08% \[median, 34%; interquartile range, 15--60%\], respectively), there was no statistically significant difference in DFS between the two groups (DFS hazard ratio, 1.001; *P* = .834). The three kinetic curve patterns presented by CAD were not significantly difference in DFS between the two groups (*P* \> .05).

![Magnetic resonance (MR) images with computer-aided detection (CAD) Color Overlay Map in a 66-year-old Woman with grade 2 invasive ductal carcinoma in the left breast.\
(**A**) Axial contrast-enhanced T1-weighted MR image shows a 26-mm irregular mass (arrows). (**B**) Axial maximum-intensity-projection MR image shows CAD color overlay over the breast mass. L1 denotes the first lesion of the left breast. Areas in red, yellow, and blue indicate a rapid washout-type delayed enhancement, plateau-type delayed enhancement, and persistent-type delayed enhancement pattern, respectively. **(C)** Kinetic curve graph showing rapid initial enhancement and rapid washout-type curve. The initial peak enhancement value was 559%. With respect to the delayed phase enhancement, 9% of the mass showed washout, 50% of the mass showed a persistent-type curve, and 41% showed a plateau-type curve. Regional recurrence was diagnosed in the ipsilateral axillary lymph node 26 months after surgery.](pone.0195756.g001){#pone.0195756.g001}

![Magnetic resonance (MR) Images with Computer-aided detection (CAD) Color Overlay Map in a 71-year-old Woman with grade 2 invasive ductal carcinoma in the right breast.\
(**A**) Axial contrast-enhanced T1-weighted MR image shows a 15-mm irregular mass (arrows). (**B**) Axial maximum-intensity-projection MR image shows a CAD color overlay over the breast mass. R1 denotes the first lesion of the right breast. Areas in red, yellow, and blue indicate rapid washout-type delayed enhancement, plateau-type delayed enhancement, and persistent-type delayed enhancement patterns, respectively. **(C)** Graph of the kinetic curve shows rapid initial enhancement and rapid washout-type curve. The initial peak enhancement value was 119%. With respect to the delayed phase enhancement, 39% of the mass showed washout, 4% of the mass showed a persistent-type curve, and 58% showed a plateau-type curve. There was no recurrence during the 65-month follow-up period.](pone.0195756.g002){#pone.0195756.g002}

10.1371/journal.pone.0195756.t001

###### Univariate Cox proportional hazard analysis of clinicopathological variables with survival outcomes.

![](pone.0195756.t001){#pone.0195756.t001g}

  Variables                        No. of patients (recurrence)   Hazard ratio    95% CI      *P* value       
  -------------------------------- ------------------------------ --------------- ----------- --------------- ----------
  Mean age (years)                 51.2 (28--80)                  49.5 (26--76)   0.988       0.954, 1.023    0.497
  T stage                                                                                                     
      1                            169 (62.8%)                    14 (43.8%)      Reference                   
      2                            90 (33.5%)                     16 (50.0%)      2.053       1.002, 4.207    0.049
      3                            9 (3.3%)                       2 (6.3%)        2.777       0.631, 12.223   0.177
      4                            1 (0.4%)                       0 (0%)          0           0.000, ∞        0.997
  N stage                                                                                                     
      0                            170 (63.2%)                    17 (53.1%)      Reference                   
      1                            77 (28.6%)                     9 (28.1%)       1.153       0.514, 2.586    0.731
      2                            16 (5.9%)                      2 (6.3%)        1.258       0.291, 5.444    0.759
      3                            6 (2.2%)                       4 (12.5%)       4.836       1.626, 14.386   0.005
  Stage                                                                                                       
      1                            126 (46.8)                     10 (31.3%)      Reference                   
      2                            115 (42.8%)                    16 (50.0%)      1.667       0.756, 3.673    0.205
      3                            28 (10.4%)                     6 (18.8%)       2.580       0.938, 7.100    0.066
  Pathologic type                                                                                             
      IDC                          242 (90.0%)                    30 (93.8%)      Reference                   
      ILC                          10 (3.7%)                      1 (3.1%)        0.850       0.116, 6.233    0.873
  Others                           17 (6.3%)                      1 (3.1%)        0.663       0.090, 4.862    0.686
  Histologic grade                                                                                            
      1                            88 (32.7%)                     2 (6.3%)        Reference                   
      2                            114 (42.4%)                    13 (40.6%)      4.490       1.013, 19.896   0.048
      3                            67 (24.9%)                     17 (53.1%)      9.782       2.260, 42.342   0.002
  ER                                                                                                          
      Positive                     202 (75.1%)                    11 (34.4%)      Reference                   
      Negative                     67 (24.9%)                     21 (65.6%)      5.243       2.527, 10.880   \<0.0001
  PR                                                                                                          
      Positive                     185 (68.8%)                    10 (31.2%)      Reference                   
      Negative                     84 (31.2%)                     22 (68.8%)      4.402       2.084, 9.299    0.0001
  HER2                                                                                                        
      Positive                     59 (21.9%)                     5 (15.6%)       Reference                   
      Negative                     210 (78.1%)                    27 (84.4%)      1.511       0.582, 3.923    0.397
  p53                                                                                                         
      Positive                     91 (33.8%)                     14 (43.8%)      Reference                   
      Negative                     178 (66.2%)                    18 (56.3%)      0.675       0.336, 1.357    0.270
  Molecular subtype                                                                                           
      Luminal                      203 (75.5%)                    12 (37.5%)      Reference                   
      HER2-enriched                30 (11.2%)                     2 (6.3%)        1.160       0.260, 5.182    0.846
      Triple-negative              36 (13.4%)                     18 (56.3%)      7.093       3.412, 14.745   \<0.0001
  Ki-67                                                                                                       
      \>14%                        164 (61.0%)                    25 (78.1%)      Reference                   
      ≤14%                         105 (39.0%)                    7 (21.9%)       0.460       0.199, 1.063    0.069
  LVI                                                                                                         
      Present                      86 (32.0%)                     14(43.8%)       Reference                   
      Absent                       183 (68.0%)                    18 (56.3%)      0.609       0.303, 1.225    0.164
  EIC                                                                                                         
      Present                      54 (20.1%)                     7 (21.9%)       Reference                   
      Absent                       215 (79.9%)                    25 (78.1%)      0.960       0.416, 2.220    0.924
  Operation method                                                                                            
      Breast-conserving surgery    218 (81.0%)                    24 (75.0%)      Reference                   
      Mastectomy                   51 (19.0%)                     8 (25.0%)       1.368       0.614, 3.045    0.443
  Resection margin                                                                                            
      Negative                     215 (79.9%)                    26 (81.3%)      Reference                   
      Close (\<2 mm) or positive   54 (20.1%)                     6 (18.8%)       0.901       0.371, 2.189    0.817
  Adjuvant chemotherapy                                                                                       
      No                           74 (27.5%)                     4 (12.5%)       Reference                   
      Yes                          195 (72.5%)                    28 (87.5%)      0.412       0.145, 1.175    0.097
  Adjuvant radiation therapy                                                                                  
      No                           38 (14.1%)                     6 (18.8%)       Reference                   
      Yes                          231 (85.9%)                    26 (81.2%)      1.462       0.601, 3.559    0.403
  Adjuvant endocrine therapy                                                                                  
      No                           70 (26.0%)                     19 (59.4%)      Reference                   
      Yes                          199 (74.0%)                    13 (40.6%)      3.968       1.961, 8.065    0.0001

CI = confidence interval, IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor 2, LVI = Lymphovascular invasion, EIC = Extensive intraductal component

10.1371/journal.pone.0195756.t002

###### Univariate Cox proportional hazard analysis of morphologic and kinetic features on MR imaging with survival outcomes.

![](pone.0195756.t002){#pone.0195756.t002g}

  Variables                                                        No. of patients (recurrence)   Hazard ratio       95% CI         *P* value       
  ---------------------------------------------------------------- ------------------------------ ------------------ -------------- --------------- -------
  Mass shape                                                                                                                                        
      Oval                                                         40 (14.9%)                     5 (15.6%)          Reference                      
      Round                                                        27 (10.0%)                     3 (9.4%)           0.926          0.221, 3.875    0.916
      Irregular                                                    202 (75.1%)                    24 (75.0%)         1.020          0.389, 2.673    0.968
  Mass margin                                                                                                                                       
      Circumscribed                                                25 (9.3%)                      3 (9.4%)           Reference                      
      Not circumscribed                                            244 (90.7%)                    29 (90.6%)         1.072          0.327, 3.520    0.909
  Mass internal enhancement                                                                                                                         
      Homogeneous                                                  32 (11.9%)                     2 (6.2%)           Reference                      
      Heterogeneous                                                204 (75.8%)                    22 (68.8%)         1.829          0.430, 7.779    0.414
      Rim enhancement                                              33 (123%)                      8 (25.0%)          4.004          0.850, 18.858   0.079
  Peak signal intensity (%)[\*](#t002fn001){ref-type="table-fn"}   252.13 (77--986)               310.19(132--559)   1.004          1.002, 1.006    0.001
  Early phase enhancement [§](#t002fn002){ref-type="table-fn"}                                                                                      
      Medium (%)                                                   7.96                           4.00               0.980          0.948, 1.013    0.234
      Rapid (%)                                                    92.08                          96.03              1.020          0.987, 1.054    0.236
  Delayed phase enhancement [§](#t002fn002){ref-type="table-fn"}                                                                                    
      Persistent (%)                                               21.22                          19.3               0.997          0.982, 1.013    0.732
      Plateau (%)                                                  40.69                          41.56              1.001          0.983, 1.021    0.886
      Washout (%)                                                  38.08                          39.19              1.001          0.989, 1.014    0.834
  Kinetic curve presented by CAD                                                                                                                    
      Type 1 (delayed persistent enhancement pattern)              2 (0.7%)                       0 (0%)             Reference                      
      Type 2 (delayed plateau enhancement pattern)                 13 (4.8%)                      2 (6.3%)           4072785.2191   0, Inf          0.997
      Type 3 (delayed washout enhancement pattern)                 254 (94.4%)                    30 (93.7%)         3274787.6777   0, Inf          0.997

\* Numbers represent the mean values with ranges

§ Numbers represent percentages

CI = confidence interval

Multivariate analysis revealed that higher peak enhancement (DFS hazard ratio, 1.004 \[95% confidence interval \[CI\]: 1.001, 1.006\]; *P =* .013) and triple-negative subtype (DFS hazard ratio, 21.060 \[95% CI: 2.675, 165.780\]; *P* = .004) were independently associated with worse DFS outcomes ([Table 3](#pone.0195756.t003){ref-type="table"}). Survival analysis for DSS was not performed because there were only six deaths in our study population \[[@pone.0195756.ref024]\].

10.1371/journal.pone.0195756.t003

###### Multivariate Cox proportional hazard analysis of clinicopathological variables and MR imaging kinetic parameters with survival outcomes.

![](pone.0195756.t003){#pone.0195756.t003g}

  Variable                     Disease-free survival               
  ---------------------------- ----------------------- ----------- ----------------
  Peak enhancement             0.013                   1.004       1.001, 1.006
  T stage                                                          
      1                                                Reference   
      2                        0.220                   1.669       0.737, 3.779
      3                        0.215                   3.046       0.524, 17.698
      4                        0.998                   0.000       0.000, ∞
  N stage                                                          
      0                                                Reference   
      1                        0.591                   1.267       0.534, 3.004
      2                        0.836                   0.851       0.185, 3.914
      3                        0.081                   3.040       0.872, 10.598
  Histologic grade                                                 
      1                                                Reference   
      2                        0.131                   3.227       0.704, 14.784
      3                        0.176                   3.162       0.596, 16.775
  Molecular subtype                                                
      Luminal                                          Reference   
      HER2-enriched            0.306                   3.538       0.314, 39.828
      Triple-negative          0.004                   21.060      2.675, 165.780
  Adjuvant endocrine therapy                                       
      No                       0.263                   3.282       0.409, 26.305
      Yes                                              Reference   

CI = confidence interval, HER2 = human epidermal growth factor receptor 2

Correlation between MR kinetic parameters and clinical-pathological variables {#sec015}
-----------------------------------------------------------------------------

The correlation between CAD-derived MR kinetic features with clinicopathological variables are presented in [Table 4](#pone.0195756.t004){ref-type="table"}. Higher peak enhancement was significantly associated with a higher T stage, higher clinical stage, and a higher histologic grade. Pathologic diagnosis of invasive ductal carcinoma, higher histologic grade, and triple-negative subtype were significantly associated with a higher washout component on the delayed enhancement phase on DCE MR imaging. Higher histologic grade, ER negativity, PR negativity, and p53 positivity were associated with a higher mean percentage volume of rapid enhancement components on early phase enhancement. On the contrary, lower histologic grade, ER positivity, PR positivity, and p53 negativity were associated with a higher mean percentage volume of medium enhancement components on early phase enhancement. Persistent enhancement on delayed phase was seen in tumors with a lower histologic grade.

10.1371/journal.pone.0195756.t004

###### Relationship between MR imaging kinetic features and various clinicopathological findings.

![](pone.0195756.t004){#pone.0195756.t004g}

  Variable                        Peak signal intensity   Early enhancement phase   Delayed enhancement phase                                                                           
  ------------------------------- ----------------------- ------------------------- --------------------------- ------- --------- ------- --------- ------- --------- ------- --------- -------
  T stage                                                 \<0.0001                                              0.865             0.865             0.615             0.149             0.611
      1                           235.634                                           8.139                               91.896            21.980            40.783            37.208    
      2                           293.528                                           6.680                               93.359            20.141            39.509            40.371    
      3                           297.818                                           6.418                               93.636            15.273            52.727            32.182    
      4                           239.000                                           0.000                               100.000           1.000             45.000            54        
  N stage                                                 0.097                                                 0.971             0.971             0.373             0.950             0.412
      0                           248.460                                           7.264                               92.775            21.979            40.481            37.530    
      1                           278.151                                           7.687                               92.337            17.514            40.921            41.584    
      2                           245.833                                           9.171                               90.889            25.500            41.667            32.889    
      3                           294.200                                           8.360                               91.700            25.100            43.700            31.000    
  Stage                                                   0.0003                                                0.797             0.801             0.620             0.615             0.366
      1                           232.765                                           7.512                               92.529            21.882            40.596            37.508    
      2                           283.611                                           7.097                               92.931            19.560            40.238            40.216    
      3                           262.971                                           9.317                               90.7353           23.1765           43.6471           33.1471   
  Pathologic type                                         0.585                                                 0.401             0.407             0.054             0.485             0.015
      IDC                         259.768                                           7.106                               92.927            19.950            40.427            39.615    
      ILC                         262.273                                           10.706                              89.455            32.636            46.727            20.473    
      Others                      233.778                                           12.087                              87.944            30.056            42.556            27.556    
  Histologic grade                                        0.032                                                 0.029             0.030             0.019             0.299             0.006
      1                           234.644                                           8.908                               91.144            26.713            41.589            31.701    
      2                           266.126                                           9.327                               90.709            19.527            41.939            38.552    
      3                           271.833                                           3.356                               96.667            17.169            38.179            44.610    
  ER                                                      0.661                                                 0.039             0.040             0.247             0.181             0.053
      Positive                    256.612                                           8.841                               91.202            22.035            41.686            36.259    
      Negative                    262.386                                           4.376                               95.648            18.555            38.602            42.878    
  PR                                                      0.505                                                 0.038             0.040             0.344             0.273             0.110
      Positive                    255.364                                           9.035                               91.010            21.972            41.632            36.362    
      Negative                    263.717                                           4.776                               95.245            19.262            39.226            41.564    
  HER2                                                    0.085                                                 0.401             0.406             0.560             0.206             0.189
      Positive                    278.141                                           5.944                               94.078            19.636            38.234            42.126    
      Negative                    252.949                                           7.965                               92.076            21.391            41.473            37.132    
  p53                                                     0.376                                                 0.026             0.027             0.064             0.128             0.550
      Positive                    265.543                                           4.550                               95.476            17.568            42.962            39.467    
      Negative                    254.429                                           9.134                               90.908            22.866            39.618            37.512    
  Molecular subtype                                       0.765                                                 0.096             0.098             0.210             0.149             0.016
      Luminal                     255.586                                           8.879                               91.163            22.133            41.903            35.945    
      HER2 enriched               267.188                                           4.025                               96.000            14.225            35.500            50.284    
      Triple-negative             263.870                                           4.264                               95.759            20.604            39.463            39.985    
  Ki-67                                                   0.177                                                 0.086             0.087             0.103             0.955             0.163
      \>14%                       264.524                                           6.236                               93.799            19.301            40.831            39.866    
      ≤14%                        247.813                                           9.72                                90.313            23.914            40.707            35.373    
  LVI                                                     0.143                                                 0.056             0.057             0.167             0.023             0.747
      Present                     270.710                                           4.875                               95.160            18.341            44.150            37.482    
      Absent                      252.134                                           8.859                               91.179            22.349            39.110            38.548    
  EIC                                                     0.056                                                 0.759             0.760             0.851             0.021             0.081
      Present                     251.295                                           6.934                               93.099            21.528            45.574            32.820    
      Absent                      260.088                                           7.688                               92.350            20.888            39.568            39.560    
  Operation method                                        0.055                                                 0.069             0.069             0.640             0.339             0.303
      Breast-conserving surgery   252.649                                           6.653                               93.384            20.702            40.290            38.984    
      Mastectomy                  281.509                                           11.152                              88.881            22.312            42.814            34.953    
  Mass shape                                              0.056                                                 0.856             0.855             0.822             0.066             0.188
      Oval                        247.111                                           7.557                               92.467            19.409            35.978            44.667    
      Round                       219.933                                           9.169                               90.867            22.870            37.540            39.567    
      Irregular                   265.628                                           7.314                               92.726            21.092            42.173            36.723    
  Mass margin                                             0.569                                                 0.981             0.972             0.623             0.802             0.795
      Circumscribed               247.643                                           7.610                               92.393            23.089            39.964            36.929    
      Not circumscribed           259.399                                           7.528                               92.513            20.805            40.869            38.324    
  Mass internal enhancement                               0.120                                                 0.836             0.839             0.201             0.679             0.094
      Homogeneous                 231.029                                           6.335                               93.677            14.732            38.324            46.973    
      Heterogeneous               258.372                                           7.871                               92.168            22.260            41.227            36.510    
      Rim enhancement             280.561                                           6.678                               93.366            19.383            40.390            40.195    

IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor 2, LVI = Lymphovascular invasion, EIC = Extensive intraductal component

Discussion {#sec016}
==========

Multivariate survival analysis revealed that patients with breast cancer who showed a higher peak enhancement (DFS hazard ratio, 1.004 \[95% CI: 1.001, 1.006\]; *P* = .013) on DCE breast MR imaging and triple-negative subtype (DFS hazard ratio, 21.060 \[95% CI: 2.675, 165.780\]; *P* = .004) had worse DFS. Higher peak enhancement was significantly associated with a higher T stage, higher clinical stage, and higher histological grade. Pathological diagnosis of invasive ductal carcinoma, higher histologic grade, and triple-negative subtype were significantly associated with a higher washout component on the delayed enhancement phase on DCE MR imaging. Our study showed that higher peak enhancement was associated with poorer DFS as well as tumor aggressiveness. In addition, higher washout component was representative of tumor aggressiveness.

Until now, most studies on MR kinetic features using CAD have focused on correlations with histopathologic findings. Leong et al. \[[@pone.0195756.ref018]\] found that a higher peak signal intensity was seen in ER-negative, PR-negative, and triple-negative tumors, compared to ER-positive, PR-positive, and non-triple-negative tumors. Kinetic features on DCE MR imaging are known to be dependent on the tumor perfusion flow, microvessel density, vascular permeability, and volume of extracellular-extravascular space composition \[[@pone.0195756.ref025]--[@pone.0195756.ref027]\]. Among CAD-derived kinetic parameters, peak enhancement is considered to reflect the concentration of the contrast agent in both intravascular and extravascular interstitial spaces \[[@pone.0195756.ref008]\]. In previous reports, high microvessel density and increased vascular permeability were associated with a higher nuclear grade \[[@pone.0195756.ref028]\], axillary lymph node metastasis, and distant metastasis \[[@pone.0195756.ref004], [@pone.0195756.ref021], [@pone.0195756.ref029]\]. Other studies have shown that peak enhancement was significantly greater among patients with lymph node metastasis and lymph node extracapsular extension \[[@pone.0195756.ref030], [@pone.0195756.ref031]\]. We believe that these results might explain the relationship between the peak enhancement on DCE MR imaging and poor prognosis.

Regarding delayed phase kinetic features, a washout kinetic pattern has been reported to correlate with a higher histologic grade, higher Ki-67 expression, increased vascular permeability, and HER2-enriched subtype \[[@pone.0195756.ref018], [@pone.0195756.ref032], [@pone.0195756.ref033]\]. In addition, a higher vascular permeability due to increased expression of vascular endothelial growth factor typically found in fast-growing tumors, may cause a higher washout component \[[@pone.0195756.ref008], [@pone.0195756.ref034]\]. Based on these prior results, we expected that a higher washout component on delayed phase enhancement might be associated with a poorer prognosis. In our study, a higher washout component on delayed phase enhancement was associated with the pathological diagnosis of invasive ductal carcinoma, triple-negative subtype, and a higher histologic grade. However, contrary to expectations, there was no statistically significant association between the amount of washout component and survival outcomes. This result was different to that of a recent study; Kim et al. \[[@pone.0195756.ref035]\] evaluated the association between CAD-generated kinetic features and DFS of patients with primary operable breast cancer, reporting that a higher peak enhancement and washout component were associated with poorer DFS. When comparing with their study, profiles of CAD-generated kinetic features were very different. For example, the mean value of washout component in patients with recurrence was much lower than that of ours (10.38% vs. 39.19%). We speculate that these differences might be caused by using different machines or different protocols. Therefore, using same threshold of CAD-generated features obtained from other institution might be not feasible. Larger studies may be necessary to provide more comprehensive information.

In our study, none of the included morphological findings (shape, margin, internal enhancement) were significantly associated with DFS. Tumors with an irregular shape often occur in high grade breast cancer \[[@pone.0195756.ref036]\]. However, there was no significant difference in the current study.

In addition to MR imaging, the evaluation of dynamic patterns on breast imaging has also been applied to other modalities. Contrast-enhanced ultrasound (CEUS) imaging has been introduced for the evaluation of tumor kinetics and it enables determinations of the diffusion pattern and real-time quantification of the contrast agent \[[@pone.0195756.ref037]--[@pone.0195756.ref039]\]. Several quantitative parameters could be automatically calculated on CEUS from the time-intensity curve as follows: peak intensity; time to peak intensity; mean transit time; slope; rise time; and area under the time-intensity curve. CEUS facilitates the functional evaluation of microcirculation and hemodynamic characteristics without extravascular enhancement, which is seen in contrast-enhanced CT and MRI. However, there are no standardized criteria for differentiating between malignant and benign tumors because of different US machines and contrast agents. In addition, there is no general consensus about the methods of imaging acquisition, protocol of contrast agent injection, and ROI setting for time-intensity curve analysis. CEUS is not routinely used in clinical practice because it is difficult to scan an entire breast within a few minutes and time-consuming post-imaging analysis in real-time examinations \[[@pone.0195756.ref040]\]. Contrast enhanced spectral mammography (CESM) is currently increasing in use, which combines the relative ease, low cost, and practicality of mammography with the high sensitivity of MRI \[[@pone.0195756.ref041]--[@pone.0195756.ref043]\]. CESM uses intravenous contrast media to obtain the images of enhancing structures. However, dynamic enhancement pattern could not be shown because CESM only shows the existence of enhancement. In the present study, we evaluated the value of CAD-derived kinetic features and our results showed that they might have the potential to be used to characterize tumor aggressiveness and predict the patients' outcome.

We only included patients who underwent 1.5-T MR imaging because Jansen et al \[[@pone.0195756.ref044]\] demonstrated that kinetic curves might not be completely consistent across three different MR imaging systems with the same field strength (1.5-T). In another study, qualitative measures of curve shape were not consistent across different field strengths, even when the acquisition parameters were standardized; the maximum percent signal enhancement was significantly higher at 3 T than at 1.5 T \[[@pone.0195756.ref045], [@pone.0195756.ref046]\]. Further studies are required to investigate differences between various MR imagers.

Our study had some limitations. First, this study had a relatively short follow-up period (mean, 55.2 months). It is well known that women with ER-positive tumors remain at risk for late recurrences after primary treatment, which might partly account for the small number of patients with recurrence, making it difficult to observe a robust survival outcome \[[@pone.0195756.ref047]\]. Second, our results might be difficult to generalize because they were based on a single center, mass lesions, a single imaging protocol, and single CAD system. Third, we could not evaluate inter- or intra- observer agreement of MR kinetic values because the CAD reports were stored prospectively. However, the same results are likely between observers given that we used a standardized ROI policy for choosing image slices that revealed the largest diameter and only mass lesions (non-mass enhancements were excluded). In our experience, significant segmentation differences are markedly decreased in mass lesions compared with non-mass enhancement lesions. In addition, the purpose of our study was not to evaluate the diagnostic accuracy of CAD, but observational survival analysis. Fourth, although these factors might have affected CAD-derived values, we did not consider the effect of the patient's motion or field inhomogeneity. Finally, of the 32 recurrences, 2 recurrences were detected within the first 6 months from the initial diagnosis, and these could have been due to residual disease.

In conclusion, our findings suggested that preoperative MR imaging kinetic features assessed using a commercially available CAD have the potential to predict survival outcomes. Patients with breast cancer who showed a higher peak enhancement on breast MR imaging may exhibit a worse DFS. In addition, peak enhancement and volumetric analysis of the early and delayed phase enhancements of breast cancers showed correlation with tumor stage, pathological findings, and histological grade, which are indicators of tumor aggressiveness.
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